Germ cell tumor (GCT) is a rare malignancy accounting for 2-3% of all pediatric tumors. The overall survival rate of children and adolescents with GCT is more than 80% after adopting combined therapy. The aim of this study is to review clinical presentation, management, and outcome in a single-center series with extracranial GCT. Clinical characteristics, pathologic presentations, and survival outcomes of 101 children with GCT, treated at our hospital from 1988 to 2011, were analyzed. Sixty-two of patients were female and 39 of them were male. Fifty-eight (57%) patients had gonadal tumor (24 testicular, 34 ovarian), 43 (43%) extragonadal. Histologically, teratomas were found most frequently (26 mature, 10 immature), followed by yolk sac tumors (n: 33), mixed malignant tumors (n: 13), embryonal carcinoma (n: 10), disgerminoma (n: 8) and seminoma (n: 1). Twenty-six patients were diagnosed as mature teratoma and we excluded them in the evaluation of staging and survival. Five-year overall and relaps-free survival were 80.3% (mean follow-up time: 215.8 months) and 73.4% (mean follow-up time: 176.2 months), respectively. Five-year survival rates were 93.2% and 90.2% in malign GCTs diagnosed after 1999.
Gonadal and extragonadal germ cell tumors (GCT) are infrequent in childhood, occurring at a rate of 2.4 cases per million children and representing approximately 1% of cancers diagnosed in persons younger than 15 years. Until recently, the myriad of histologic subtypes and sites of origin and the paucity of cases hindered the standardization of care for such children. 1 GCTs form an important group of gonadal neoplasms and are also found in a number of extragonadal sites like the mediastinum, pineal and sacrococcygeal regions and retroperitoneum. Although there are considerable differences between GCTs occurring in different anatomical locations they exhibit a remarkable homology, and are considered as a group. 2, 3 GCTs show numerous histologic subtypes. The histologic features of each subtype are independent of presenting clinical characteristics; tumor biology and clinical behavior vary with site of origin, state, and age of the patient. 4 The introduction of platinum-based chemotherapy resulted in cure rate in excess of 80%, even in advanced disease.
GCT were admitted to our institution between 1988 and 2011. The cut-off date for analysis of these patients was February 2012. Their clinical characteristics, pathologic features, methods of treatment, relaps and survival outcomes were retrospectively evaluated. The tumors were classified according to the Dehner system. 5 Twenty-six patients were diagnosed as mature teratoma and we excluded them in the evaluation of staging and survival analyses. The Children's Oncology Group (COG) classification system for staging was used. 1 The study was approved by the Ethics Committee of the Yıldırım Beyazıt University (Report number: 2017/08). The quantitative variables were described using median and range; qualitative variables were described using frequency and percentages. We used chi-square test to examine the relationship between pairs of variables. Overall survival (OS) and relaps free survival (RFS) distributions were estimated by the method of Kaplan-Meier survival analyses. Using the Cox proportional hazards regression model, multivariate analyses were performed to determine the variables that were independently predictive of prognosis. A p <0.05 was used for statistical significance.
Results
During the period of 23 years, 101 patients with extracranial GCTs were admitted to our clinic. Out of the 101 patients, 62 were female and 39 were male. Their median age was 72 months (0-192 months). The vast majority of patients presented with a combination of symptoms and signs; however, the most frequent primary symptoms and signs were abdominal pain and abdominal mass (n: 44 patients). Abdominal pain, either acute, cronic, or both was reported in 23 patients. The second most frequent symptom, abdominal distension by the abdominal or pelvic mass, was noted in 21 patients, associated with pain in all. The third important symptom was increase in testicular size with palpable mass. Other symptoms and signs included sacrococcygeal mass, constipation, nausea, vomiting, urinary symptoms and precocious puberty. One patient had acute abdominal condition. The duration of symptoms ranged from 1 day to 6 months, except for one patient who presented with a 2 years (since birth) history of sacrococcygeal mass. The clinical presentation of these patients are summarized in Table I . Figure 1 reveals the bimodal age distribution of GCTs. The first peak was observed during the first 2 years of life both in girls and boys. The second peak started at the age of 8 years in girls and at the age of 12 years in boys. The lowest incidence was found at the age of 5-6 years. Overall, GCTs were more common in girls than in boys (M:F, 1: 1.5). However, among children under 5 years of age, the tumors were more common in boys (M:F, 1.2:1). In the older age group, GCTs were more common in girls (34 females vs. 4 males) (M:F, 0.11:1, p< 0.001). This striking female predominance relates to the high number of ovarian tumors (31 ovarian vs. 4 testicular) in older patients.
Site of origin and diagnostic imaging
The site of the GCTs varied with genders and age. Fifty-eight (57%) patients had gonadal tumor (24 testicular, 34 ovarian), 43 (43%) extragonadal (29 sacrococcygeal, 13 retroperitoneum, 1 neck). Although bilaterality has been reported in gonadal GCTs, no contralateral tumours were identified in this series.
The ovarian tumors were most frequent in the age groups 5 to 10 years and over 10 years. The testis tumors were most frequent in the 1 to 5 years.
Sacrococcygeal and retroperitoneal regions were the most common extragonadal site of origin. Of the extragonadal GCTs, diagnosed during the first year of life, two-thirds (66%) ocurred at the sacrococcygeal region. Abdominal ultrasound was the most common investigation, performed in all patients.
Computed tomography was performed for 24 patients. Magnetic resonance imaging was performed only in one patient.
Tumor markers
Alpha-feto-protein (AFP) and human beta chorionic gonadotropine (B-HCG) levels were normal (based on age) in all patients with mature teratomas (26 patients). We detected high AFP levels in 43 of 75 patients with malignant GCTs, high B-HCG levels in 4 of 75 patients. Both AFP and B-HCG levels were elevated in 4 patients. We found normal AFP and B-HCG levels in 17 patients with malignant GCTs (six with immature teratomas, four with embryonal carcinoma, two with seminomas, two with yolk sac tumors, two with mixed malignant tumors and one with disgerminoma). Unfortunately, in two of them tumor markers were measured after surgery (one had stage I disease, another one had stage II disease). Seven patients were not studied for AFP and B-HCG because of socio economic difficulties.
Histology and staging
Histologically, teratomas were found most frequently (26 mature, 10 immature), followed by yolk sac tumors (n: 33), mixed malignant tumors (n: 13), embryonal carcinoma (n: 10), disgerminoma (n: 8) and seminoma (n: 1).
We observed that the GCT histology in children vary with sex and age groups ( Figure 2 and Table II ). Figure 2 shows that in infants, the vast majority of GCTs are teratomas. Malignant non-germinomatous GCT, the vast majority of which were yolk-sac tumors, were most common at the age of 13-60 months. Disgerminomas predominantly developed after the age of 5 years. Disgerminomas and teratomas constituted the most frequent histological subtype during adolescence.
Twenty-six patients were diagnosed as mature teratoma and they were excluded from the evaluation of staging and survival. Nineteen (median 21 months) after diagnosis. Fourteen patients were lost to follow up at a median follow up of 3 months (ranged, 1-15). Thirteen patients were lost without disease at a median follow up of 28 months (ranged, 12-139).
Sixteen (21.3%) patients had relapse in 3 to 18 months. The median time for tumor recurrence was 10 months. For the 16 relapses, 9 were locoregional recurrence and 7 were systemic metastases. Six out of them were referred to us for relaps treatment after primary was managed elsewhere. These patients were in the early 1990s, surgical centers are operated, stage 1 evaluated and followed without consultation of pediatric oncology clinic. (Table III) . 
Prognostic Factors
We investigated prognostic factors by univariate and multivariate analysis. Age group, sex, site, histology, stage, tumor marker, and treatment were tested; they did not have a prognostic value. These methods identified patients treated between 1999 and 2011 as having decreased mortality in comparison with those treated in the earlier period (in the multivariate analysis, HR 0.16; 95% CI: 0.028-0.989; p: 0.049).
Discussion
Pediatric GCTs are rare tumors. Their overall incidence can be estimated as 0.9/100,000 children up to 15 years. They arise due to variation from normal differentiation of germ cells and include a heterogeneous group of neoplasms with remarkable variability concerning histology and site of presentation: Benign, malignant and immature GCTs can be observed in children and adolescents with different rates, also according to age. 3 We have confirmed that the GCT localization and histological subgroups in children vary among genders and age groups. The clinical characteristics found in this study are similar to other national and international studies related to the issue. [6] [7] [8] [9] [10] [11] [12] Median age at diagnosis varied according to tumor site, histology, and sex. In a large population-based cohort study from Germany, including 1,442 cases up to 15 years of age, there was a bimodal age distribution. In this study, the first peak was observed during the first 2 years of life. The second rise of incidence started at the age of 7 years in girls and at the age of 10 years in boys. As the lowest incidence was found at the age of 5-6 years. 8 In another study from US, incidence peaks were observed before the age of 1 year and from ages 15 to 19 years in both boys and girls. In this study, the incidince of GCTs was smilar in boys and girls in the age group of patients ages birth to 9 years, whereas the incidence was much higher in boys in the group ages 10 to 19 years. 6 In accordance with other studies, bimodal age distribution was observed in our patients. The first peak was observed during the first 2 years of life both in girls and boys. 
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The second peak started at the age of 8 years in girls and at the age of 12 years in boys. The lowest incidence was found at the age of 5-6 years. Among children under 5 years of age, the tumors were more common in boys (M:F, 1.2:1), while in the older patients, there was a striking female predominance (M:F, 0.11:1, p< 0.001). This might be attributed to referral of male adolescent patients to adult centers in our country.
Tumor markers are important in the diagnosis, diagnosis of relapse and follow-up. High AFP and beta-HCG levels were detected in 63% and 11% of the studied patients, respectively.
Teratomas are the most common GCTs observed in most published series. 6, 7, 9 In our series, the most frequently recognized histological types were teratomas and yolk sac tumors. Teratomas constitute the vast majority of GCTs in neonate and that the incidence peak of YST follows approximately 1 year later.
Mature teratomas with normal tumor markers were kept in regular follow-up, but patients having malignant GCTs need follow-up regarding appropriate therapy and survival.
Immature teratomas, although not truly malignant, have been treated as malignant neoplasms in the past because of their potential to recur as malignant tumours. Either immature teratomas or immature teratomas with microscopic foci of yolk sac tumours have been included in the group of malignant GCTs in many series 10, 12 ; chemotherapy has been given to patients with grade II or III immature teratomas. In our series, three patients with immature teratomas received multi-agent chemotherapy because of relaps and elevated AFP and all remained free of disease at follow-up.
The prognosis in GCTs did not improve until the late 1970s, when the VAC regimen became the standart chemotherapy in GCTs. Since the introduction of platinum-based agents in pediatric chemotherapy regimens, the survival rates for children with malignant GCTs ranging from 75% to more than 90%. [13] [14] [15] With accurate staging, complete resection, and chemotherapy for malignant GCTs, patients are expected to have excellent survival rates. In a study frm Turkey, Akyüz et al. 11 reported OS and EFS in ovarian tumors as 68% and 57%, respectively.
Feltbower et al. 15 reported the 5-year survival rates as 93-95% for gonadal GCT, and 70-75% for extragonadal GCT. Mann et al. 14 9 In a more recent large population-based study from Germany, 5-year survival rate was reported as 92% for gonadal and extragonadal GCTs. 10 In our series, OS rate (80.3%), which is lower than that of other series, could be partially explained by the high number of patients with advanced disease. Additionaly, of 11 patients in our series, 10 died between 1988 and 1998. It was remarkable that within this period, six patients were operated in other surgical centers, followed-up without consulting pediatric oncology departments, and admitted to the clinic with advanced-stage relapse thereafter. Only two of the patients who were diagnosed after 1999 have relapsed so far. It was also considerable that except for one, all other cases had abandoned the treatment within this period. As clearly seen in our study group, survival rates increased from 1988-1998 to 1999-2011 and the number of patients who escaped from treatment decreased over the years.
For extracranial malignant GCTs, the tumour site, age and elevated AFP have been proven to be of importance as prognostic factors. 13, [16] [17] [18] Gonadal GCTs have a significantly better prognosis compared to extragonadal tumours. We could not identify site, age and elevated AFP as a prognostic factor. In our study group, the prognosis of malign CCTs has improved over time through advances in treatment. In children with malignant GCTs, survival rates can be improved owing to factors such as advancement in diagnostic and therapeutic techniques, improved supportive care, and a multidisciplinary approach.
In conclusion, some significant differences in clinical features were documented. Among children under 5 years of age, the tumors were more common in boys (M:F, 1.2:1), while in the older patients, there was a striking female predominance (M:F, 0.11:1, p< 0.001). This might be attributed to referral of male adolescent patients to adult centers in our country. They were similar to patients in other large pediatric series with respect to sites of origin, age at presentation in relationship to primary site, histology and sex.
Our study has some limitations. This is a retrospective study from a single national institution. Our data has failed to demonstrate any correlation between tumor stage and survival. This can be explained by the very few numbers of patients with stage IV. Unfortunately, our infrastructure capacity to accurately determine stage at dignosis was limited at that time.
However, this series confirms the good overall results that can be achieved in children with malignant GCTs. As parallel to the recent developments across the world, the rate of life expectancy has increased due to the elevation witnessed in general health services in Turkey.
The advances in multidisciplinary approach to pediatric oncology care have led to dramatically improved survival for children with GCT in Turkey.
